HENLIUS (02696.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec23

Dr. Zhu Jie, CEO of Henlius, to speak at the 44th J.P. Morgan Healthcare Conference

13:54

Dec19

Fosun Pharma and Subsidiary Fosun Henlius Obtain FDA Approval

11:32

F.H. ChinaBio Secures FDA Approval for HLX18 Biosimilar Phase I Clinical Trial

09:04

Dec16

China 银河 Securities First Coverage and Recommended HLX Oncology

07:34

Dec14

Fosun Pharma's HLX10 New Indication Application Accepted and Added to Priority Review

09:25

Dec12

Fuli Oncology Drug HANSIZHUANG Receives Priority Review from China's NMPA

08:48

Schedules & Filings

Schedules

Filings

Aug25

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 1.543 B, Net Income 213.5 M, EPS 0.3928

Mar24

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 1.584 B, Net Income 230.95 M, EPS 0.4249

Aug26

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 1.475 B, Net Income 207.55 M, EPS 0.3814

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change